Frozen Tumor Tissue Microarray Technology for Analysis of Tumor RNA, DNA, and Proteins

Por Schoenberg Fejzo, Marlena, Slamon, Dennis J.
Publicado em 2001

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Por Finn, Richard S., Aleshin, Alexey, Slamon, Dennis J.
Publicado no Breast Cancer Res (2016)

Potential Utility of an Expression Array Signature for Predicting Anthracycline Responsiveness or Resistance

Por Press, Michael F., Gordon, Michael A., Slamon, Dennis J.
Publicado em 2012

A model-based approach for assessing in vivo combination therapy interactions

Por Lopez, Angela M., Pegram, Mark D., Slamon, Dennis J., Landaw, Elliot M.
Publicado em 1999

The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers

Por Oh, Juliana J., Koegel, Ashley, Phan, Diana T., Razfar, Ali, Slamon, Dennis J.
Publicado em 2007

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation

Por Wu, Yanyuan, Alvarez, Monica, Slamon, Dennis J, Koeffler, Phillip, Vadgama, Jaydutt V
Publicado em 2010

Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds

Por Watanabe, Masaru, Fiji, Hannah D. G., Guo, Lea, Chan, Lai, Kinderman, Sape S., Slamon, Dennis J., Kwon, Ohyun, Tamanoi, Fuyuhiko
Publicado em 2008

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

Por Lu, Nu T., Raizer, Jeffrey, Gabor, Erwin P., Liu, Natalie M., Vu, James Q., Slamon, Dennis J., Barstis, John L.
Publicado no J Immunother Cancer (2015)

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study

Por Britten, Carolyn D, Gomes, Antoinette S, Wainberg, Zev A, Elashoff, David, Amado, Rafael, Xin, Yan, Busuttil, Ronald W, Slamon, Dennis J, Finn, Richard S
Publicado em 2012

Systemic Therapy for Metastatic Renal Cell Carcinoma: A Review and Update

Por Logan, Joshua E, Rampersaud, Edward N, Sonn, Geoffrey A, Chamie, Karim, Belldegrun, Arie S, Pantuck, Allan J, Slamon, Dennis J, Kabbinavar, Fairooz F
Publicado em 2012

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

Por Fejzo, Marlena S., Anderson, Lee, von Euw, Erika M., Kalous, Ondrej, Avliyakulov, Nuraly K., Haykinson, Michael J., Konecny, Gottfried E., Finn, Richard S., Slamon, Dennis J.
Publicado em 2013

Pleiotrophin mediates hematopoietic regeneration via activation of RAS

Por Himburg, Heather A., Yan, Xiao, Doan, Phuong L., Quarmyne, Mamle, Micewicz, Eva, McBride, William, Chao, Nelson J., Slamon, Dennis J., Chute, John P.
Publicado no J Clin Invest (2014)

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-posit...

Por Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Publicado em 2014

HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells

Por Wilson, Cindy A, Cajulis, Elaina E, Green, Jennifer L, Olsen, Taylor M, Chung, Young Ah, Damore, Michael A, Dering, Judy, Calzone, Frank J, Slamon, Dennis J
Publicado em 2005

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Por Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J
Publicado em 2009

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

Por Tap, William D, Gong, Ke-Wei, Dering, Judy, Tseng, Yiou, Ginther, Charles, Pauletti, Giovanni, Glaspy, John A, Essner, Richard, Bollag, Gideon, Hirth, Peter, Zhang, Chao, Slamon, Dennis J
Publicado em 2010

Identification of common predictive markers of in vitro response to the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell...

Por Garon, Edward B., Finn, Richard S., Hosmer, Wylie, Dering, Judy, Ginther, Charles, Adhami, Shahriar, Kamranpour, Naeimeh, Pitts, Sharon, Desai, Amrita, Elashoff, David, French, Tim, Smith, Paul, Slamon, Dennis J.
Publicado em 2010

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Por McDermott, Martina SJ, Browne, Brigid C, Conlon, Neil T, O’Brien, Neil A, Slamon, Dennis J, Henry, Michael, Meleady, Paula, Clynes, Martin, Dowling, Paul, Crown, John, O’Donovan, Norma
Publicado no Mol Cancer (2014)

FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells

Por Bernardo, Gina M., Bebek, Gurkan, Ginther, Charles L., Sizemore, Steven T., Lozada, Kristen L., Miedler, John D., Anderson, Lee A., Godwin, Andrew K., Abdul-Karim, Fadi W., Slamon, Dennis J., Keri, Ruth A.
Publicado em 2012

Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small cell lung cancer

Por Garon, Edward B., Pietras, Richard J., Finn, Richard S., Kamranpour, Naeimeh, Pitts, Sharon, Márquez-Garbán, Diana C., Desai, Amrita J., Dering, Judy, Hosmer, Wylie, von Euw, Erika M., Dubinett, Steven M., Slamon, Dennis J.
Publicado em 2013